Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgenusAGEN -2.32%43 EV-to-EBITDA is 2.17 as of Aug. 18, 2026. GuruFocus rates AGEN with a GF Score™ of 43/100 and a GF Value™ of $3.78 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 401 Biotechnology companies, Agenus ranks better than 75.06% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Agenus's enterprise value is $337.2 Mil.
Agenus's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $155.8 Mil. Therefore, Agenus's EV-to-EBITDA for today is 2.17.
The historical rank and industry rank for Agenus's EV-to-EBITDA or its related term are showing as below:
AGEN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.97 Med: -2.65 Max: 15.95
Current: 2.17
During the past 13 years, the highest EV-to-EBITDA of Agenus was 15.95. The lowest was -8.97. And the median was -2.65.
AGEN's EV-to-EBITDA is ranked better than 75.06% of 401
companies
in the Biotechnology industry
Industry Median: 13.8
vs AGEN: 2.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-18), Agenus's stock price is $7.155.
Agenus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $2.580. Therefore, Agenus's PE Ratio (TTM) for today is 2.77.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Agenus's share price for today is $7.155.
Agenus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Agenus's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Agenus's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agenus EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agenus's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Agenus's EV-to-EBITDA falls into.
Agenus's current Enterprise Value is $337.2 Mil.
Agenus's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $155.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agenus (AGEN) has a EV-to-EBITDA of 2.17 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Agenus. According to the industry distribution chart, Agenus ranks #100 out of 401 companies in the Biotechnology industry, placing it in the top 24.9%.
Is Agenus' EV-to-EBITDA too high?
Agenus' current EV-to-EBITDA is 2.17. The Biotechnology industry median EV-to-EBITDA is 13.80. Agenus' value of 2.17 is 84.3% below this industry median. Based on the distribution chart, Agenus ranks #100 out of 401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Agenus has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Agenus' EV-to-EBITDA compare to FULC and IRD?
According to the Biotechnology industry distribution chart, Agenus ranks #100 out of 401 companies for EV-to-EBITDA. This places Agenus in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.80. Agenus' value of 2.17 is 84.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agenus's current EV-to-EBITDA of 2.17 is 84.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Agenus. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agenus's current EV-to-EBITDA is 2.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agenus stock overvalued right now?
Based on GuruFocus' analysis, Agenus (AGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.78, compared to a current price of $7.16 — trading 89.3% above its estimated fair value. The current EV-to-EBITDA is 2.17 and 84.3% below the Biotechnology industry median of 13.80. Agenus' overall GF Score™ is 43/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Agenus (AGEN), the current EV-to-EBITDA is 2.17 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agenus (AGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Agenus stock appears to be overvalued.
The current stock price of $7.16 is trading 89.3% above its estimated GF Value™ of $3.78.
GuruFocus considers Agenus to be Significantly Overvalued.
Key valuation signals for AGEN:
EV-to-EBITDA: 2.17
GF Value™: $3.78 vs. price of $7.16 (89.3% above fair value)
Industry Position: 84.3% below the Biotechnology median (#100 of 401)
No single metric tells the full story. See the AGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
43GF Score
Get the complete analysis for AGEN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGEN has been successfully added to your 
